In an interview conducted during the 2021 Genitourinary Cancers Symposium, Lucas Nogueira, MD, visiting investigator at Memorial Sloan-Kettering Cancer Center, New York, NY, discusses results from the phase 1 study of WST11 vascular-targeted photodynamic therapy in patients with upper tract urothelial carcinoma. This therapy involves the use of padeliporfin, an intravascular photosensitizing agent. According to Dr Nogueira, the promising efficacy combined with low treatment-related toxicity support further investigation of this therapy.